Develops and commercializes pharmaceutical solutions for health security threats. Focuses primarily on antiviral drugs for infectious diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
If every debt were paid off today, $154.4M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 25% — still a thick cushion, though costs have been eating into it lately.
There is $155.0M in the vault; even if every debt were paid off, $154.4M would remain.
It pays out $1.20 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 8% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The growth engine is running at low revs right now. Report-card grade: 10/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 18/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, SIGA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SIGA does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: earnings execution.